Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Abstract Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates...

Full description

Bibliographic Details
Main Authors: Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Journal of Hematology & Oncology
Subjects:
Immunotherapy
PD-1/PD-L1
Combination therapy
PD-L1 regulation
Online Access:https://doi.org/10.1186/s13045-022-01242-2

Internet

https://doi.org/10.1186/s13045-022-01242-2

Similar Items